Article Sidebar

PDF (Tiếng Việt)
Published: 2023-09-20
Abstract Views: 147
Views PDF (Tiếng Việt): 206
DOI: https://doi.org/10.52852/tcncyh.v169i8.1826
Issue
Vol. 169 No. 8 (2023)
Section
Các bài báo
How to Cite
Hậu, T. T., & Thế, Đào M. (2023). 18. The efficacy of Platinum-based chemotherapy in stage IV non-small cell lung cancer patients haboring common EGFR mutation after resistance to Tyrosine Kinase inhibitors at K Hospital. Journal of Medical Research, 169(8), 147-154. https://doi.org/10.52852/tcncyh.v169i8.1826

18. The efficacy of Platinum-based chemotherapy in stage IV non-small cell lung cancer patients haboring common EGFR mutation after resistance to Tyrosine Kinase inhibitors at K Hospital

Tran Thi Hau, Dao Minh The

Main Article Content

Abstract

Tyrosine kinase inhibitor therapy brings high efficacy in treating non-small cell lung cancer with a mutation in the epidermal growth factor receptor. However, after a time of treatment, resistance is inevitable. Platinum-based chemotherapy is considered as standard treatment for TKIs resistant patients without any secondary acquired mutation. This is a cross-sectional descriptive retrospective study on 31 patients with stage IV non-small cell lung cancer harboring common EGFR mutation after resistance to TKIs then treated with platinum-based chemotherapy from January 2019 to June 2023 at K hospital. We describe the clinical and subclinical features and evaluate the effectiveness of platinum-based chemotherapy as follows: the study showed a mean age of 59.45 (29 - 73 yd). The male/female rate was 1.2/1. Bone and contralateral lung metastases got the highest rate at 38.7%; brain metastases occurred in 35.5% of all cases; liver metastases got the lowest rate at 12.9%. The overall response rate was 19.3%, disease control rate was 67.7%. Median disease-free survival was six months and median overall survival was ten months. The study showed platinum-based chemotherapy for stage IV non-small cell lung cancer patients after resistance to TKIs brought a high disease control rate and median overall survival.

Article Details

Keywords

Non-small cell lung cancer, EGFR, TKIs, platinum-based chemotherapy

References

1. Chen YM. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer. J Chin Med Assoc. 2013; 76: 249-57.
2. Langer CJ. Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer? J Clin Oncol. 2013; 31: 3303-3306.
3. Mok TS, Wu YL, et al. Gefitinib or carboplatin paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10): 947–957.
4. Rosell R, Carcereny E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3): 239–246.
5. Soria JC, Ohe Y, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018; 378: 113-125.
6. Wu JY, Shih JY, Yang CH, et al. Second-line treatments after first-line gefitinib therapy in advanced non small cell lung cancer. Int J Cancer. 2010; 126(1): 247–255.
7. Kosaka T, Yatabe Y, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004; 64: 8919–23.
8. Fred Hsu, Alex De Caluwe, et al. EGFR mutation status on brain metastases from non-small cell lung cancer. Lung Cancer. 2016 Jun;96:101-7.
9. Papadimitrakopoulou VA, Mok TS, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol (2020) 31(11): 1536-44. doi: 10.1016/j.annonc.2020.08.2100.
10. Anita B, Safiye D, et al. Reporting of Incidence and Outcome of Bone Metastases in Clinical Trials Enrolling Patients with Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma-A Systematic Review. Cancers (Basel). 2021 Jul; 13(13): 3144.
11. Yen-Han T, Hsiu-Ying H, et al. Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI). J Chemother. 2016; 28(1): 50-8.
12. Chih-Jen Yang, Ming-Ju Tsai, et al. Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment. OncoTargets and Therapy. 2016: 9 1579–1587.
13. Park S, Keam B, Kim SH, et al. Pemetrexed singlet versus nonpemetrexed-based platinum doublet as second-line chemotherapy after first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor failure in non-small cell lung cancer patients with EGFR mutations. Cancer Res Treat. 2015; 47(4): 630–637.
14. Wu JY, Shih JY, Yang CH, et al. Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer. Int J Cancer. 2010; 126(1): 247–255.